Skip to content

Total debt at other companies

Exelixis logo
ExelixisEXEL
$169.54M-9.4%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$15.48M-9.4%
CG Oncology logo
CG OncologyCGON
$7.58M+631%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $32.79M.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's total debt?
Tango Therapeutics (TNGX) reported total debt of $32.79M in Q1 2026.
How has Tango Therapeutics's total debt changed year-over-year?
Tango Therapeutics's total debt decreased by 11.3% year-over-year, from $36.95M to $32.79M.
What is the long-term trend for Tango Therapeutics's total debt?
Over 5 years (2020 to 2025), Tango Therapeutics's total debt has grown at a 33.6% compound annual growth rate (CAGR), from $7.88M to $33.57M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.